5-Bromo-DMT, or 5-bromodimethyltryptamine, is a halogenated analogue of N,N-dimethyltryptamine. A bromine atom replaces hydrogen at the 5-position of the indole ring. Unlike many established psychedelic tryptamines, it has attracted recent interest because preclinical research found serotonin-receptor activity and neuroplasticity-related effects without producing the usual head-twitch response in mice.
Chemistry and structural relationship
5-Bromo-DMT retains the indole-ethylamine structure of DMT and its two N-methyl groups. The bromine substituent is attached to the 5-position of the aromatic ring. It belongs to a small group of halogenated DMT analogues studied to determine how substitutions on the indole ring affect serotonin-receptor signalling and behavioural effects.
Receptor pharmacology
A 2025 study compared 5-bromo-DMT with 5-fluoro-DMT and 5-chloro-DMT. The compounds were assessed using in-vitro receptor assays, computational modelling and animal experiments. 5-Bromo-DMT activated the 5-HT2A receptor, but did not produce a measurable head-twitch response in mice under the conditions tested. The authors interpreted this as a separation between receptor activation and the behavioural marker commonly used to identify psychedelic-like activity (Neuropharmacology of halogenated DMT analogs, 2025).
Neuroplasticity research
The same study reported increased expression of immediate-early genes associated with neuronal plasticity in the mouse prefrontal cortex and hippocampus. It also found increased dendritic growth in cultured cortical neurons. In a mouse model of stress-related depressive behaviour, a single experimental administration reduced depressive-like behaviour.
These findings are preclinical. They do not demonstrate an antidepressant effect in people, and the absence of a head-twitch response in mice does not prove that the compound is non-hallucinogenic in humans.
Human effects and safety
No controlled human study has established the subjective effects, pharmacokinetics or safety of 5-Bromo-DMT. The receptor and animal findings warrant further investigation, without establishing a therapeutic role or a reliable human toxic range.
What remains unknown
Human metabolism, acute toxicity, dependence potential and long-term effects have not been adequately characterised. The current evidence is based on laboratory assays, cell experiments and animal models. The available data do not establish 5-Bromo-DMT as a non-hallucinogenic treatment.
Related tryptamines
5-Bromo-DMT is related to 5-MeO-DMT, DMT and other halogenated DMT analogues, including 5-fluoro-DMT and 5-chloro-DMT. The bromine substitution gives it a distinct receptor and behavioural profile in the available preclinical study.
